Regulatory Synergies in Device Innovation

Slides:



Advertisements
Similar presentations
Dr. Michael E. Oehlsen International Policy Analyst International Programs Team - Office of the Director Center for Veterinary Medicine Food and Drug Administration.
Advertisements

Columbia University IRB IRB 101 September 21, 2005 George Gasparis, Executive Director, CU IRB Asst. V.P. and Sr. Asst. Dean for Research Ethics.
Good Clinical Practice GCP
Executive summary prepared by some members of the ICH Q9 EWG for example only; not an official policy/guidance July 2006, slide 1 ICH Q9 QUALITY RISK MANAGEMENT.
Regulatory Authority Governing Clinical Trials Anthony J. Minisi, MD Director, Cardiology Fellowship Program.
Industry Perspective on Challenges for Product Developers - Drugs Christine Allison, M.S., RAC Associate Regulatory Consultant, Global Regulatory Affairs.
Progress in FDA’s Drug Product Quality Initiative Janet Woodcock, M.D. November 13, 2003.
Research in the Office of Cellular, Tissue and Gene Therapies: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation.
Request for Information & Capability Statements Richland Acquisitions Post-FY 2018 November 17-19, 2015.
FDA Regulatory and Compliance Symposium Industry Collaboration & Interactions with Health Professionals: Can Conflicts of Interest be Properly Managed?
Examining Drug Quality Regulation Douglas C. Throckmorton, MD Deputy Director Center for Drug Evaluation and Research Public Meeting on 21 CFR February,
Cancer Clinical Trials Office Clinical Trials & Research Training Oct2014.
RAC Regulatory Affairs Certification
Regulatory Updates Health Sciences Authority Singapore
CLI and Device Intervention Across the Pacific – An FDA View
Rachel Neubrander, PhD Division of Cardiovascular Devices
Evolving Importance of Post-Approval Studies
Clinical Review Process for New Drug Development and Application
Placebo / Standard of Care (PSoC)
Office of Medical Devices II,
U.S. FDA Center for Devices and Radiological Health Update
OUS Data: What does the CE Mark Really Mean?
FDA Division of Cardiovascular Devices
Collaborative Program: Is It Ready for Valve Studies?
Jeff Shuren, MD, JD Center for Devices and Radiological Health U. S
ICH-GCP Avinash Kondawar M. Pharm Lead CRA
FDA’s IDE Decisions and Communications
Director, Asia Pacific Japan and U.S. Clinical Operations
FDA Perspective on Cardiovascular Device Development
Balancing Pre and Postmarket Requirements Different Scenarios
Balancing Regulation and Innovation: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.
How to Apply for and Receive Industry Funding for Investigator Sponsored Research Chuck Simonton MD, FACC, FSCAI Chief Medical Officer Abbott Vascular.
CMS and FDA The History and Horizon of Regulatory Coordination
Reasonable Assurance of Safety and Effectiveness: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division.
The FDA Early Feasibility Study Pilot and the Innovation Pathway
Japan-USA Synergies: Academic View
FDA Guidance on Early Feasibility Studies, Including First-in-Human
Medical Device Evaluation Division,
What Kind of Aspects can Physicians Look Forward To? US Physician View
Data Managers’ Forum What’s in it for us?
Michelle Limoli, Pharm.D.
Lessons Learned Through HBD: The Industry’s View
11th GHTF CONFERENCE WASHINGTON DC OCTOBER 2007 SG5: CLINICAL EVALUATION STATUS REPORT SUSANNE LUDGATE Name MHRA Date 2007.
Introduction of New Technology: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.
Benefits of US EFS: A Clinical Perspective
Medical Device Regulatory Essentials: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.
Early Feasibility in the USA –An Academic View
Lessons Learned: Past Present and Future Japan-USA Regulatory Interactions Erica Takai, PhD US Food and Drug Administration
US Early Feasibility Studies (EFS)
Lessons Learned Through HBD: The Regulator’s View - US FDA
FDA-CDRH in the Next Decade A Vision for Change
Jeff Shuren, MD, JD Center for Devices and Radiological Health U. S
Erica Takai, PhD for Andrew Farb, M.D.
Quality System.
ILAC Marketing & Communications
Lessons Learned Through HBD: The Regulator’s View - PMDA Perspective
Reflections on International Cooperation
Combination products The paradigm shift
Strategic & Operational Planning:
PhUSE Computational Science
Beyond Academia.
PhUSE Computational Science Working Groups
EDUCATE: A NESTcc Demonstration Project Regulatory Perspective
Implantable Medical Devices: Accelerating Standards Development to Streamline Regulation Joshua Price | August 2,
Data Visualizations Working Group
FDA Perspective Marco Cannella, PhD Senior Lead Reviewer
Kaisa Immonen EPF Director of Policy
Cardiovascular Device Development and Approval: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of.
Dr Manisha Shridhar Regional Advisor WHO-SEARO
Collaboration Across the Lifecycle of Treatment Development and Safe Use – Contributions from Stakeholders Early Development Later Development Regulatory.
Presentation transcript:

Regulatory Synergies in Device Innovation Japan – USA Regulatory Synergies in Device Innovation Bram Zuckerman, MD Director, FDA Division of Cardiovascular Devices FDA Center for Devices and Radiological Health

Disclosure Statement of Financial Interest I DO NOT have a financial interest, arrangement or affiliation with one or more organizations that could be perceived as a real or apparent conflict of interest.

Mission Statements FDA: “Protecting the public health by assuring that … medical devices intended for human use are safe and effective. Advancing the public health by helping to speed product innovations”. PMDA: “Our obligation is to protect the public health by assuring safety, efficacy and quality of pharmaceuticals and medical devices…monitoring of their post-marketing safety…providing relief services for adverse health effects.

Japan – USA Regulatory Synergies Harmonization by Doing (HBD) What is the HBD Initiative? HBD launched in December 2003 seek regulatory convergence between FDA and MHLW-PMDA Pre and post-market review of cardiovascular device technology Utilize parallel development for application submissions and review of actual medical device projects Objective - eliminate redundancies, added costs, and time delays inherent in separate development

Advantages of Participating in HBD Time and cost for development solely in US Time and cost for development solely in Japan ≧ Time and cost for Communication (Meetings, etc.) Time & cost for “simultaneous” development in US and Japan Essential to have good planning

Harmonization by Doing (HBD) HBD is a “hands-on” approach to medical device development Involves Japanese and US stakeholders from: Government Academia Industry

HBD Structure Currently four working groups WG1: Pre-market clinical trial protocols WG2: Post-market data WG3: Clinical trial infrastructure WG4: Regulatory convergence Application of “proof of concept” (POC) principles Development steps will help identify specific obstacles and workable solutions to global development POC projects proposed to WGs by interested stakeholders

Accomplishments HBD Program is one important global strategy for improving public health in Japan and US Regulatory/scientific meetings in Japan and US since 2004 First Think Tank Meeting in Japan, 2005 Second Think Tank Meeting in US, 2007 Third Think Tank Meeting in Japan, 2008 Fourth Think Tank Meeting in US, 2009 Upcoming Fifth Think Tank Meeting in Japan, 2011

HBD is an Incubator for New Programs: PMDA-FDA Collaborative Scheme Paradigm for US and Japanese regulators to discuss device and trial information and/or regulatory submissions US and Japanese regulators work together with sponsor toward solutions Include sponsors in 3-way communications as appropriate Protect confidential and trade secret information Does not adversely affect US approval time lines

Regulatory Synergies USA and Japan Similarities > Differences Similar Missions Similar processes Similar trial design requirements Emphasize Development of Innovative Technology Total Product Lifecycle

Where Can I Find Out More? General information, announcements, and updates on HBD: http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/InternationalInformation/ucm053067.htm